Jianyang Hu

809 total citations
16 papers, 511 citations indexed

About

Jianyang Hu is a scholar working on Molecular Biology, Cancer Research and Toxicology. According to data from OpenAlex, Jianyang Hu has authored 16 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 4 papers in Cancer Research and 3 papers in Toxicology. Recurrent topics in Jianyang Hu's work include RNA Research and Splicing (5 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Cancer Mechanisms and Therapy (2 papers). Jianyang Hu is often cited by papers focused on RNA Research and Splicing (5 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Cancer Mechanisms and Therapy (2 papers). Jianyang Hu collaborates with scholars based in China, Hong Kong and United States. Jianyang Hu's co-authors include Wen‐Cai Ye, Dongmei Zhang, Lijuan Deng, Zhenjian Zhuo, Nan Yao, Xueping Lei, Junshan Liu, Huayi Yang, Zhixian Mo and Chuying Huo and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Scientific Reports.

In The Last Decade

Jianyang Hu

15 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianyang Hu China 11 354 100 92 51 46 16 511
Chunpu Zou China 12 258 0.7× 80 0.8× 86 0.9× 80 1.6× 53 1.2× 24 458
Sima Mansoori Derakhshan Iran 5 325 0.9× 103 1.0× 69 0.8× 64 1.3× 49 1.1× 22 533
Grégory Tufo France 3 381 1.1× 129 1.3× 104 1.1× 35 0.7× 39 0.8× 3 583
Clarissa Esmeralda Halim Singapore 7 349 1.0× 109 1.1× 155 1.7× 60 1.2× 43 0.9× 9 640
Robert Kleszcz Poland 15 356 1.0× 119 1.2× 94 1.0× 33 0.6× 37 0.8× 39 590
Yanxia Li China 13 291 0.8× 106 1.1× 71 0.8× 70 1.4× 29 0.6× 25 463
Shreya Kar Singapore 6 290 0.8× 101 1.0× 138 1.5× 98 1.9× 46 1.0× 8 500
Poomy Pandey United States 6 445 1.3× 97 1.0× 119 1.3× 46 0.9× 28 0.6× 6 658

Countries citing papers authored by Jianyang Hu

Since Specialization
Citations

This map shows the geographic impact of Jianyang Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianyang Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianyang Hu more than expected).

Fields of papers citing papers by Jianyang Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianyang Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianyang Hu. The network helps show where Jianyang Hu may publish in the future.

Co-authorship network of co-authors of Jianyang Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Jianyang Hu. A scholar is included among the top collaborators of Jianyang Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianyang Hu. Jianyang Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Chen, Junhao, Jianyang Hu, Qiqi Wang, et al.. (2025). Fangchinoline suppresses melanoma metastasis by inducing senescence of circulating tumor cells. Biomedicine & Pharmacotherapy. 193. 118770–118770.
2.
Hu, Jianyang, Lin He, Hao Huang, et al.. (2025). Targeting TUBB2B inhibits triple-negative breast cancer growth and brain-metastatic colonization. Journal of Experimental & Clinical Cancer Research. 44(1). 55–55. 3 indexed citations
3.
Hu, Jianyang, Hao Huang, Tan Wu, et al.. (2024). FOSL1 is a key regulator of a super-enhancer driving TCOF1 expression in triple-negative breast cancer. Epigenetics & Chromatin. 17(1). 34–34. 1 indexed citations
4.
Wang, Liping, et al.. (2024). A Potential “Anti-Warburg Effect” in Circulating Tumor Cell-mediated Metastatic Progression?. Aging and Disease. 0–0. 19 indexed citations
5.
Huang, Hao, Jianyang Hu, Qinghua Huang, et al.. (2021). Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling. Nature Communications. 12(1). 2242–2242. 76 indexed citations
6.
Sun, Haiyan, Tong Ou, Jianyang Hu, et al.. (2021). Nitazoxanide impairs mitophagy flux through ROS-mediated mitophagy initiation and lysosomal dysfunction in bladder cancer. Biochemical Pharmacology. 190. 114588–114588. 16 indexed citations
7.
Hu, Jianyang, Hao Huang, Saravanan Ramakrishnan, et al.. (2021). TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis. British Journal of Cancer. 126(1). 57–71. 17 indexed citations
8.
Zhou, Min, Weiping Li, Jian Li, et al.. (2020). Phase-separated condensate-aided enrichment of biomolecular interactions for high-throughput drug screening in test tubes. Journal of Biological Chemistry. 295(33). 11420–11434. 27 indexed citations
9.
Liu, Junshan, Chuying Huo, Huihui Cao, et al.. (2019). Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway. Phytomedicine. 61. 152843–152843. 94 indexed citations
10.
Chen, Liping, Minfeng Chen, Jianyang Hu, et al.. (2017). Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin. Pharmacological Research. 123. 130–142. 59 indexed citations
11.
Sun, Haiyan, Maohua Huang, Nan Yao, et al.. (2017). The cycloartane triterpenoid ADCX impairs autophagic degradation through Akt overactivation and promotes apoptotic cell death in multidrug-resistant HepG2/ADM cells. Biochemical Pharmacology. 146. 87–100. 21 indexed citations
12.
Lei, Xueping, Minfeng Chen, Jianyang Hu, et al.. (2016). In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathways.. PubMed. 6(4). 843–58. 20 indexed citations
13.
14.
Zhuo, Zhenjian, Jianyang Hu, Xiaolin Yang, et al.. (2015). Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo. Scientific Reports. 5(1). 16185–16185. 87 indexed citations
15.
Hu, Jianyang, Xueping Lei, Zhenjian Zhuo, et al.. (2015). Bufalin Induces Apoptosis of MDA-MB-231 Cell Through Activation of JNK/p53 Pathway. 4(2). 1 indexed citations
16.
Wang, Gang, Xiaoyan Dong, Jianyang Hu, et al.. (2011). Long-term ex vivo monitoring of in vivo microRNA activity in liver using a secreted luciferase sensor. Science China Life Sciences. 54(5). 418–425. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunpu Zou Breakdown of academic impact, for papers by Sima Mansoori Derakhshan Breakdown of academic impact, for papers by Grégory Tufo Breakdown of academic impact, for papers by Clarissa Esmeralda Halim Breakdown of academic impact, for papers by Robert Kleszcz Breakdown of academic impact, for papers by Yanxia Li Breakdown of academic impact, for papers by Shreya Kar Breakdown of academic impact, for papers by Poomy Pandey
Rankless by CCL
2026